Hiprabovis IBR
ATC code
Species
Cattle (calves and adult cows).
Indications
For the active immunisation of cattle from 3 months of age against bovine herpes virus type 1 (BoHV1) to reduce the clinical signs of Infectious bovine rhinotracheitis (IBR) and field virus excretion.
Onset of immunity: 21 days after completion of the basic vaccination scheme.
Duration of immunity: 6 months after completion of the basic vaccination scheme.
Dose to be administered and administration route
Cattle: from the age of 3 months onwards.
Administer one dose of 2 ml by intramuscular injection in the neck muscles.
Reconstitute the lyophilisate with the entire contents of the supplied solvent to obtain a suspension for injection. A transparent pinkish liquid is obtained after reconstitution.
Recommended vaccination programme:
The recommended initial dose is 1 injection of 2 ml of the reconstituted vaccine per animal. The animal should be revaccinated 3 weeks later with the same dose.
Thereafter a single booster dose of 2 ml should be administered every six months.
The method of administration is by intramuscular route, in the neck muscles. The injections should be preferably administered on the alternate sides of the neck. The solvent should be allowed to warm to a temperature between 15 ºC and 20 ºC before reconstitution of the lyophilisate. Shake well before use. Avoid the introduction of contamination during reconstitution and use. Use only sterile needles and syringes for administration.
Adverse reactions
Cattle (calves and adult cows):
Common (1 to 10 animals / 100 animals treated): | Elevated temperature1. Injection site inflammation2. |
Rare (1 to 10 animals / 10 000 animals treated): | Hypersensitivity reaction3. |
1A slight increase in body temperature up to 1 °C within 4 days following vaccination. An increase in rectal temperature up to 1.63 ºC in adult cows and up to 2.18 ºC in calves may be observed. This transient rise in temperature is spontaneously resolved within 48 hours without treatment and it is not related to a febrile process.
2A transient inflammation at the inoculation site in cattle within 72 hours post-vaccination. This slight swelling lasts for less than 24 hours in most cases.
3Including anaphylaxis (sometimes fatal). In such cases, an appropriate symptomatic treatment should be administered.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
